Update of the drug resistance mutations in HIV-1: March 2013.
作者信息
Johnson Victoria A, Calvez Vincent, Gunthard Huldrych F, Paredes Roger, Pillay Deenan, Shafer Robert W, Wensing Annemarie M, Richman Douglas D
机构信息
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
出版信息
Top Antivir Med. 2013 Feb-Mar;21(1):6-14.
Abstract
摘要
相似文献
1
Update of the drug resistance mutations in HIV-1: March 2013.
Top Antivir Med. 2013 Feb-Mar;21(1):6-14.
2
2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2011 Nov;19(4):156-64.
3
Assessments of HIV drug resistance mutations in resource-limited settings.
Clin Infect Dis. 2011 Apr 15;52(8):1058-60. doi: 10.1093/cid/cir093.
4
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
AIDS Rev. 2008 Apr-Jun;10(2):67-84.
5
Update of the drug resistance mutations in HIV-1: 2007.
Top HIV Med. 2007 Aug-Sep;15(4):119-25.
6
Update of the drug resistance mutations in HIV-1: December 2009.
Top HIV Med. 2009 Dec;17(5):138-45.
7
2015 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
8
Update of the drug resistance mutations in HIV-1: Spring 2008.
Top HIV Med. 2008 Apr-May;16(1):62-8. doi: 10.1007/s11750-007-0034-z.
9
2019 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2019 Sep;27(3):111-121.
10
2014 Update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
引用本文的文献
1
Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering.
Pharmaceuticals (Basel). 2025 Mar 1;18(3):356. doi: 10.3390/ph18030356.
2
A survey of resistance mutations to reverse transcriptase inhibitors (RTIs) among HIV-1 patients in northeast of Iran.
Mol Biol Res Commun. 2024;13(3):117-125. doi: 10.22099/mbrc.2024.48729.1895.
3
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
PLoS One. 2023 Jan 20;18(1):e0279996. doi: 10.1371/journal.pone.0279996. eCollection 2023.
4
Evidence for Recombination as an Evolutionary Mechanism in Coronaviruses: Is SARS-CoV-2 an Exception?
Front Public Health. 2022 Mar 17;10:859900. doi: 10.3389/fpubh.2022.859900. eCollection 2022.
5
Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells.
J AIDS Clin Res. 2021;12(5). Epub 2021 May 21.
6
The transmission of drug-resistant strains of HIV in heterosexual populations based on genetic sequences.
PLoS One. 2021 Dec 1;16(12):e0259023. doi: 10.1371/journal.pone.0259023. eCollection 2021.
7
Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population.
Virusdisease. 2021 Sep;32(3):480-491. doi: 10.1007/s13337-021-00725-z. Epub 2021 Jul 13.
8
The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.
Discoveries (Craiova). 2014 Dec 31;2(4):e27. doi: 10.15190/d.2014.19.
9
Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines.
Nat Commun. 2018 Dec 13;9(1):5305. doi: 10.1038/s41467-018-07753-2.
10
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Virol J. 2018 Sep 17;15(1):143. doi: 10.1186/s12985-018-1051-2.
本文引用的文献
1
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.
2
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9.
3
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0.
4
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
5
2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2011 Nov;19(4):156-64.
6
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.
7
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.
Zotero 插件